Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 41 от 154

Набира участници Фаза 2

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Follicular Lymphoma

This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.

Начало: 23.10.2024 Край: 15.09.2033 Възраст: от 18 г. Лечение

Australia, Italy Fondazione Italiana Linfomi - ETS NCT06492837

Набира участници Фаза 2

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Basal Ganglia Germinoma Diabetes Insipidus Germinoma Pineal Region Germinoma +2

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.

Начало: 22.10.2024 Край: 04.11.2033 Възраст: 3–29 г. Лечение

Australia, Canada, United States Children's Oncology Group NCT06368817

Набира участници Фаза 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-Resistant Prostate Cancer

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Начало: 22.10.2024 Край: 30.11.2028 Възраст: от 18 г. Лечение

Argentina, Brazil, Bulgaria +23 Pfizer NCT06629779

Набира участници Фаза 2

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Idiopathic Short Stature

The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).

Начало: 21.10.2024 Край: 01.12.2036 Възраст: 3–11 г. Лечение

Australia, France, Germany +3 BioMarin Pharmaceutical NCT06382155

Набира участници Фаза 1

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumor

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.

Начало: 18.10.2024 Край: 30.09.2028 Възраст: от 18 г. Лечение

Australia, China, South Korea +1 BeiGene NCT06598800

Набира участници Фаза 1

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Asthma

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.

Начало: 16.10.2024 Край: 07.06.2027 Възраст: 18–65 г. Лечение

Australia, Belgium, Canada +2 Amgen NCT06637371

Набира участници

Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)

Atrial Fibrillation

EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial). The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.

Начало: 14.10.2024 Край: 01.05.2030 Възраст: от 18 г. Превенция

Australia, Canada, Germany +4 Atrial Fibrillation Network NCT06324188

Набира участници Фаза 1

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Advanced Solid Tumor Metastatic Breast Cancer Metastatic Ovarian Cancer Metastatic Endometrial Cancer +2

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Начало: 14.10.2024 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia EtiraRx Australia Pty Ltd NCT06533332

Набира участници Фаза 2

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Neuroendocrine Tumors

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not. The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

Начало: 14.10.2024 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, Canada Australasian Gastro-Intestinal Trials Group NCT06345079

Набира участници Фаза 2

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Solid Tumours

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have. All participants take one dose of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Начало: 11.10.2024 Край: 29.12.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Boehringer Ingelheim NCT06581432

Набира участници Фаза 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumor

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.

Начало: 11.10.2024 Край: 01.01.2029 Възраст: от 18 г. Лечение

Australia, China, Denmark +4 BeOne Medicines NCT06589596

Набира участници

Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

Ischemic Stroke, Acute

Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \

Начало: 11.10.2024 Край: 01.05.2026 Възраст: от 18 г. Лечение

Australia, Canada The George Institute NCT06352619

Набира участници Фаза 1/2

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Начало: 10.10.2024 Край: 01.01.2029 Възраст: 18–75 г. Лечение

Australia, Bulgaria, Canada +8 Xencor, Inc. NCT06619990

Набира участници Фаза 2

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Episodic Migraine Chronic Migraine

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of IPN10200 to inject at each point, * The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.

Начало: 10.10.2024 Край: 15.06.2027 Възраст: 18–80 г. Лечение

Australia, Brazil, Canada +11 Ipsen NCT06625060

Набира участници Фаза 1/2

Study of LM-299 in Subjects Advanced Malignant Tumors

Malignant Tumors

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.

Начало: 09.10.2024 Край: 01.07.2027 Възраст: 18–80 г. Лечение

Australia, China LaNova Medicines Limited NCT06650566

Набира участници Фаза 1

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Solid Tumor, Adult Bladder Cancer Urothelial Carcinoma Triple-negative Breast Cancer +5

This is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the imaging study MNPR-101-D001 (actively recruiting, diagnostic study of MNPR-101-DFO\*-89Zr). * TITE-BOIN will be used to objectively determine dose increase, no dose change, or dose decrease for each group of two patients. * The treatment period consists of two 12-week cycles. Patients will receive three equal fractions of MNPR-101-PCTA-177Lu with radioactivity ranging from 480-2240 MBq on each of Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (12 weeks after Cycle 1 Day 1). * Patients will be followed for 12 weeks after their last dose of MNPR-101-PCTA-177Lu. * Patients will be imaged at specific timepoints during the study.

Начало: 08.10.2024 Край: 01.01.2027 Възраст: от 18 г. Лечение

Australia Monopar Therapeutics NCT06617169

Набира участници Фаза 1

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Extensive Stage Small Cell Lung Cancer

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Начало: 07.10.2024 Край: 27.03.2030 Възраст: от 18 г. Фундаментална наука

Australia, Belgium, China +7 Amgen NCT06598306

Набира участници Фаза 3

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Non-small Cell Lung Cancer

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Начало: 07.10.2024 Край: 04.08.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Bristol-Myers Squibb NCT06561386

Набира участници Фаза 1/2

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

Systemic Lupus Erythematosus (SLE)

A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Начало: 04.10.2024 Край: 05.06.2026 Възраст: 18–70 г. Лечение

Australia, United States DualityBio Inc. NCT06625671

Набира участници Фаза 2

ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs

Degenerative Disc Disease Disc Degeneration Lumbar Discogenic Pain

VIA Disc NP is an off-the-shelf minimally processed human nucleus pulposus tissue allograft intended to supplement degenerated intervertebral discs. The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (\> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels.

Начало: 04.10.2024 Край: 01.04.2026 Възраст: 22–85 г. Друго

Australia VIVEX Biologics, Inc. NCT06615505

1 … 39 40 41 42 43 … 154